The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
May 6th 2024
The FDA has accepted a biologics license application for subcutaneous nivolumab for adult patients eligible for approved solid tumor nivolumab indications.
Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer
May 19th 2016Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director of Urologic Oncology, University of Chicago Medicine, discusses the FDA approval of atezolizumab (Tecentriq) as a treatment for patients with with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.
PD-1 Expression on Monocytes Potential Immunotherapy Biomarker in RCC
May 13th 2016Mohammed Haseebuddin, MD, discusses results of a study which demonstrated that elevated preoperative classical monocyte PD-1 mean fluorescence intensity level and lower CM was linked to poor survival in patients with clear cell renal cell carcinoma, as well as the challenges with using PD-1 as a biomarker in these patients.
Krishna Vanaja Donkena on Using Immune Markers to Predict Survival in Bladder Cancer
May 12th 2016Krishna Vanaja Donkena, PhD, Assistant Professor of Biochemistry and Molecular Biology, Center for Individualized Medicine, Mayo Clinic, discusses using immune and checkpoint markers to predict cancer-specific survival in bladder cancer.
Liquid Imiquimod Formulation May Induce Immune Response in Bladder Cancer
TMX-101 (Vesimune), a liquid formulation of the toll-like receptor 7 agonist imiquimod, appeared safe and demonstrated preliminary clinical activity, including the potential to induce an immune response, in patients with non-muscle invasive bladder cancer.
Molecular Testing, New Biomarkers on Horizon for Immunotherapy in RCC
May 11th 2016Mark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti–PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.
Dr. Choueiri on Using Immunotherapy to Treat RCC
April 11th 2016Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses why community oncologists should utilize immunotherapy agents to treat patients with renal cell carcinoma.
Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways
March 29th 2016Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.
Dr. Krajewski on Responses With PD-1 Agents in RCC
March 17th 2016Katherine Krajewski, MD, associate director, physician, Cancer Imaging Program Fellowship, Dana-Farber Cancer Institute, assistant professor of Radiology, Harvard Medical School, discusses the range of responses seen in patients with renal cell carcinoma (RCC) who have received PD-1 agents as treatment.
Dr. Gulley on Checkpoint Inhibitors in Bladder Cancer
March 14th 2016James L. Gulley, MD, PhD, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, National Cancer Institute, discusses checkpoint inhibitors in bladder cancer.
Durvalumab Granted Breakthrough Status for Bladder Cancer
The FDA has granted a breakthrough therapy designation to durvalumab as a treatment for patients with PD-L1–positive inoperable or metastatic urothelial bladder cancer following progression on prior treatment with a platinum-based regimen.
Expert Discusses Exciting Potential for Atezolizumab in Bladder Cancer
February 15th 2016Arjun V. Balar, MD, discusses the phase II data demonstrating the efficacy of atezolizumab as a single agent, its potential as part of combination regimens, and planned clinical trials looking at immunotherapy in patients with metastatic bladder cancer.
Dr. Sharma on PD-L1 as Biomarker for Immunotherapy in Bladder Cancer
February 12th 2016Padmanee Sharma, MD, PhD, professor of Immunology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses PD-L1 as a predictive biomarker for immunotherapy in patients with bladder cancer.
FDA Issues Complete Response Letter for Immunotherapy MCNA in Bladder Cancer
February 3rd 2016The FDA issued a complete response letter to Telesta Therapeutics informing the company that its biologics license application for MCNA in bladder cancer would not be approved and that an additional phase III clinical trial was needed to adequately evaluate the immunotherapy.
Dramatic Changes on Horizon in Renal Cell Carcinoma
The optimal frontline treatment strategy for patients with metastatic renal cell carcinoma could look dramatically different in the next few years, as studies assess combination strategies and predictive biomarkers for immunotherapy and targeted therapies.